(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of 13.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Akebia Therapeutics's revenue in 2025 is $225,071,000.On average, 7 Wall Street analysts forecast AKBA's revenue for 2025 to be $64,773,185,231, with the lowest AKBA revenue forecast at $58,253,142,783, and the highest AKBA revenue forecast at $70,884,564,050. On average, 7 Wall Street analysts forecast AKBA's revenue for 2026 to be $79,315,241,648, with the lowest AKBA revenue forecast at $67,095,137,670, and the highest AKBA revenue forecast at $87,366,445,875.
In 2027, AKBA is forecast to generate $87,419,519,074 in revenue, with the lowest revenue forecast at $72,399,803,870 and the highest revenue forecast at $103,012,424,823.